Browse the corpus

Amphotericin B deoxycholate, an esteemed member of the polyene class of antifungals, has been a cornerstone in therapy against invasive fungal infections for over 5 decades. This drug has witnessed significant advancements by introducing novel lipid formulations that exhibit a reduced nephrotoxic profile compared to the traditional formulation. This comprehensive activity is designed to meticulously elucidate the indications, contraindications, pharmacological activity, adverse events, and toxicity associated with amphotericin B, equipping members of the interprofessional healthcare team with essential insights for adeptly managing mycotic infections in diverse clinical settings. Participants gain a profound understanding of the antifungal applications of amphotericin B, empowering them to contribute effectively to the collaborative care of patients grappling with fungal infections. Objectives: Identify the appropriate indications for amphotericin B therapy based on the type of fungal infection and patient characteristics. Implement proper dosing and administration strategies for amphotericin B to ensure optimal therapeutic outcomes while minimizing toxicity. Assess the patient's response to amphotericin B therapy by regularly monitoring clinical symptoms, laboratory parameters, and adverse effects. Determine a plan with other healthcare professionals, such as infectious disease specialists and pharmacists, to optimize amphotericin B therapy and ensure comprehensive patient care. Access free multiple choice questions on this topic.

Amphotericin exhibits infusion-related toxicity, which accounts for its extended administration times. Infuse slowly over 3 hours; rapid infusion can cause cardiotoxicity. Amphotericin B deoxycholate overdose can cause ventricular arrhythmias and bradycardia in patients with preexisting cardiac conditions.[36] Due to the similarity of mammalian and fungal membranes, which both contain sterols (the therapeutic target for amphotericin B), amphotericin B can exhibit cellular toxicity. In the suspected overdose of amphotericin B, treatment should be discontinued. Supportive therapy should be administered as required. Amphotericin B and its formulations are not effectively removed by dialysis.

Healthcare professionals, including physicians and advanced practice practitioners prescribing amphotericin B, should know its indications, administration, and adverse effects. Close to 80% of the patients will develop either infusion-related or renal toxicity. Before the infusion, consider pretreatment with acetaminophen, diphenhydramine, or hydrocortisone to attenuate adverse effects. Meperidine treatment may decrease the duration of rigors.[11] Following infusion, the patient's renal function requires periodic monitoring. Given the drug's interaction and adverse event profile, it is unsurprising that amphotericin B use is cautiously used. However, prescribers may need to employ it for recalcitrant infections, and consultation with the pharmacist is necessary to ensure no drug-drug interactions exist or that a different agent might achieve the desired therapeutic result. Nurses also need to understand the side effect profile of this drug and the potential for infusion reactions; if there are any concerns, the nursing staff should immediately alert the prescribing clinician. A robust, collaborative, interprofessional healthcare team effort involving physicians, infectious disease specialists, advanced practice practitioners, nurses, and pharmacists must achieve desired patient outcomes with minimal adverse effects.